EADV 2026视频特辑｜Carsten Flohr教授：特应性皮炎诊疗前沿：治疗终点、药物价值与领域新突破

英国伦敦国王学院皮肤科 Carsten Flohr 教授围绕特应性皮炎的治疗终点评估、靶向药物价值与领域前沿突破三大主题展开分享。教授结合其牵头的多项登记研究成果，解析了最小疾病活动度（MDA）与患者报告结局的相关性，指出 MDA 的评估局限性，并介绍了国际层面针对达标治疗评估体系的优化探索；同时基于欧洲多中心真实世界数据，阐述了阿布昔替尼的临床疗效与长期病情控制价值，明确其暂未实现永久阻断疾病恶性循环的病程调节作用。此外，视频还从全球流行病学研究、疾病生物学机制框架、STAT6 通路创新口服药，以及生命早期疾病预防策略等多个维度，系统呈现了特应性皮炎领域的最新进展与未来研究方向。

Professor Carsten Flohr from the Department of Dermatology, King's College London, shares insights on three core themes of atopic dermatitis: treatment endpoint assessment, the value of targeted therapies, and cutting-edge breakthroughs in the field. Drawing on findings from multiple registry studies led by him, he analyzes the correlation between Minimal Disease Activity (MDA) and patient-reported outcomes, points out the limitations of MDA as an evaluation metric, and introduces international explorations to optimize the treat-to-target evaluation system. Meanwhile, based on European multicenter real-world data, he elaborates on the clinical efficacy and long-term disease control value of abrocitinib, clarifying that the agent has not yet achieved a disease-modifying effect to permanently break the vicious cycle of the disease. In addition, the video systematically presents the latest advances and future research directions in the field of atopic dermatitis from multiple dimensions, including global epidemiological research, the biological mechanism framework of the disease, innovative oral agents targeting the STAT6 pathway, and early-life disease prevention strategies.